FY2024 Earnings Forecast for TCRX Issued By Lifesci Capital

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at Lifesci Capital lowered their FY2024 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($1.08) per share for the year, down from their prior estimate of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

A number of other analysts have also issued reports on TCRX. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Trading Down 8.2 %

TCRX opened at $4.82 on Friday. The stock has a market cap of $255.32 million, a price-to-earnings ratio of -4.55 and a beta of 0.79. The stock’s 50 day moving average price is $5.33 and its 200-day moving average price is $6.51. TScan Therapeutics has a one year low of $3.73 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.77 and a current ratio of 9.56.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP purchased a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $70,000. The Manufacturers Life Insurance Company acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $90,000. SG Americas Securities LLC acquired a new position in shares of TScan Therapeutics in the 3rd quarter valued at $78,000. Cornercap Investment Counsel Inc. acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $134,000. Finally, MetLife Investment Management LLC increased its position in shares of TScan Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after acquiring an additional 13,164 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Insiders Place Their Bets

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was purchased at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the acquisition, the director now owns 45,000 shares in the company, valued at approximately $238,050. This trade represents a 12.50 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased a total of 15,000 shares of company stock worth $82,550 over the last 90 days. Company insiders own 2.76% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.